JP6817466B2 - 緑内障の治療 - Google Patents

緑内障の治療 Download PDF

Info

Publication number
JP6817466B2
JP6817466B2 JP2019563248A JP2019563248A JP6817466B2 JP 6817466 B2 JP6817466 B2 JP 6817466B2 JP 2019563248 A JP2019563248 A JP 2019563248A JP 2019563248 A JP2019563248 A JP 2019563248A JP 6817466 B2 JP6817466 B2 JP 6817466B2
Authority
JP
Japan
Prior art keywords
dextran sulfate
glaucoma
pharmaceutically acceptable
acceptable salt
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019563248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519742A5 (https=
JP2020519742A (ja
Inventor
ブリュス，ラーズ
ブリュス，アダム
Original Assignee
ティーエックス メディック エービー
ティーエックス メディック エービー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ティーエックス メディック エービー, ティーエックス メディック エービー filed Critical ティーエックス メディック エービー
Priority claimed from PCT/SE2018/050506 external-priority patent/WO2018212708A1/en
Publication of JP2020519742A publication Critical patent/JP2020519742A/ja
Publication of JP2020519742A5 publication Critical patent/JP2020519742A5/ja
Application granted granted Critical
Publication of JP6817466B2 publication Critical patent/JP6817466B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
JP2019563248A 2017-05-17 2018-05-16 緑内障の治療 Active JP6817466B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1750615 2017-05-17
SE1750615-5 2017-05-17
US201762555848P 2017-09-08 2017-09-08
US62/555,848 2017-09-08
PCT/SE2018/050506 WO2018212708A1 (en) 2017-05-17 2018-05-16 Treatment of glaucoma

Publications (3)

Publication Number Publication Date
JP2020519742A JP2020519742A (ja) 2020-07-02
JP2020519742A5 JP2020519742A5 (https=) 2020-08-13
JP6817466B2 true JP6817466B2 (ja) 2021-01-20

Family

ID=62245395

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563248A Active JP6817466B2 (ja) 2017-05-17 2018-05-16 緑内障の治療

Country Status (12)

Country Link
US (1) US11291684B2 (https=)
EP (1) EP3532072B1 (https=)
JP (1) JP6817466B2 (https=)
KR (1) KR102331421B1 (https=)
CN (1) CN110621320B (https=)
CA (1) CA3063851C (https=)
DK (1) DK3532072T3 (https=)
ES (1) ES2777836T3 (https=)
IL (1) IL270362B (https=)
PL (1) PL3532072T3 (https=)
PT (1) PT3532072T (https=)
RU (1) RU2759998C2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3074987A1 (en) * 2017-09-08 2019-03-14 Tx Medic Ab New use of dextran sulfate
GB202008919D0 (en) * 2020-06-11 2020-07-29 Univ Birmingham Polysaccharide conpositions and therapeutic gels
CN115531417B (zh) * 2022-11-14 2024-04-09 青岛海尔生物科技有限公司 ITGA6阳性iPSC源小梁网类细胞在制备治疗高眼压疾病药物中的应用及筛选方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4238482A (en) * 1978-09-29 1980-12-09 Peyman Gholam A Intraocular infusion irrigation solution and method
DE3705669A1 (de) 1987-02-21 1988-09-01 Thomae Gmbh Dr K Verwendung von dextransulfat zur herstellung eines arzneimittels zur behandlung und prophylaxe von gefaessverengungen und gefaessverschluessen
JPH02223525A (ja) * 1988-11-16 1990-09-05 Takeda Chem Ind Ltd 血管新生阻害剤
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
US5227372A (en) 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
CA2020199C (en) 1990-06-29 2002-08-20 Daniel Bar-Shalom Uses of sulphated sugars
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
CA2331620A1 (en) 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
GB9917092D0 (en) 1999-07-22 1999-09-22 Ml Lab Plc Treatment of angiogenesis-dependent conditions
WO2005110438A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
SE0401182D0 (sv) 2004-05-05 2004-05-05 Q Med Ab Novel use of a viscoelastic composition
US20060154894A1 (en) 2004-09-15 2006-07-13 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
WO2007002139A2 (en) 2005-06-22 2007-01-04 The Trustees Of The University Of Pennsylvania Neuroprotection of retinal ganglion cells
US20140186339A1 (en) * 2006-10-27 2014-07-03 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
US20130273096A1 (en) 2011-10-05 2013-10-17 Bruce A. Daniels Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients
EP3142684A4 (en) * 2014-05-12 2018-05-23 Purdue Research Foundation Selectin and icam/vcam peptide ligand conjugates
WO2015190989A1 (en) 2014-06-12 2015-12-17 Tx Medic Ab The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
SE538503C2 (en) 2014-11-11 2016-08-16 Tx Medic Ab New dextran sulfate
SE539575C2 (en) * 2015-07-30 2017-10-17 Tx Medic Ab Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis
CN107137421A (zh) 2017-05-25 2017-09-08 青岛市中心医院 硫酸葡聚糖在制备抑制角膜血管新生药物中的应用

Also Published As

Publication number Publication date
PL3532072T3 (pl) 2020-09-21
ES2777836T3 (es) 2020-08-06
EP3532072B1 (en) 2020-01-01
EP3532072A1 (en) 2019-09-04
KR102331421B1 (ko) 2021-11-25
CA3063851C (en) 2023-09-19
IL270362B (en) 2021-04-29
BR112019024087A2 (pt) 2020-06-02
CN110621320A (zh) 2019-12-27
JP2020519742A (ja) 2020-07-02
RU2019136633A (ru) 2021-06-17
RU2759998C2 (ru) 2021-11-22
KR20200005560A (ko) 2020-01-15
US20210315920A1 (en) 2021-10-14
RU2019136633A3 (https=) 2021-06-17
PT3532072T (pt) 2020-03-05
US11291684B2 (en) 2022-04-05
CA3063851A1 (en) 2018-11-22
CN110621320B (zh) 2023-03-17
DK3532072T3 (da) 2020-04-06

Similar Documents

Publication Publication Date Title
Harun-Or-Rashid et al. Structural and functional rescue of chronic metabolically stressed optic nerves through respiration
Stepp et al. Reduced intraepithelial corneal nerve density and sensitivity accompany desiccating stress and aging in C57BL/6 mice
Williams et al. Inhibition of the classical pathway of the complement cascade prevents early dendritic and synaptic degeneration in glaucoma
Sun et al. Neuroprotective effect of minocycline in a rat model of branch retinal vein occlusion
Hill et al. Decorin reduces intraocular pressure and retinal ganglion cell loss in rodents through fibrolysis of the scarred trabecular meshwork
JP6817466B2 (ja) 緑内障の治療
Chen et al. Altered expression of nNOS/NIDD in the retina of a glaucoma model of DBA/2J mice and the intervention by nNOS inhibition
Yuan et al. Ic100, a humanized therapeutic monoclonal anti-asc antibody alleviates oxygen-induced retinopathy in mice
He et al. Association of high-mobility group box-1 with inflammationrelated cytokines in the aqueous humor with acute primary angle-closure eyes
WO2018212708A1 (en) Treatment of glaucoma
Vecino et al. Glaucoma animal models
Trofimova Molecular mechanisms of retina pathology and ways of its correction
Pastor Jimeno et al. Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences
Iwata et al. Animal models for eye diseases and therapeutics
Yang et al. Neuregulin-1 protects against acute optic nerve injury in rat model
BR112019024087B1 (pt) Uso de sulfato de dextrano ou de um sal farmaceuticamente aceitável do mesmo para tratamento, inibição ou prevenção de glaucoma
Xiao-Chen et al. A New Experimental Model of Krypton Laser-Induced Choroidal Neovascularization in Tree Shrew
LIU et al. A New Experimental Model of Krypton Laser-Induced Choroidal Neovascularization in Tree Shrew
Kokkali The role of innate immune activation in experimental glaucoma
Echevarria The Role of Interleukin-6 in Health and Disease of Retinal Ganglion Cells
Cui et al. Endothelin 2-Mediated Neuroinflammation Drives Hypertension-Associated Retinal Dysfunction
Reina-Torres et al. 10. VEGF expression is elevated in high-flow regions of mouse trabecular meshwork.
Ingensiep Establishment of multielectrode array-based retinal ex vivo stress models: hypoxia and pressure
Pan Neuroprotection through pharmacological targeting retinal immune microenvironment in retinal neurodegenerative diseases
Biagioni Fighting inflammation to save cones: anti-inflammatory approaches to slow down cone degeneration in a mouse model of retinitis pigmentosa

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200615

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200615

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201224

R150 Certificate of patent or registration of utility model

Ref document number: 6817466

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250